OTCMKTS:BIXT Bioxytran (BIXT) Stock Price, News & Analysis $0.16 +0.00 (+1.21%) As of 03:58 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesSEC FilingsShort InterestBuy This Stock About Bioxytran Stock (OTCMKTS:BIXT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Bioxytran alerts:Sign Up Key Stats Today's Range$0.16▼$0.1650-Day Range$0.10▼$0.1852-Week Range$0.06▼$0.23Volume81,458 shsAverage Volume243,761 shsMarket Capitalization$15.93 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewBioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was founded in 2008 and is headquartered in Needham, Massachusetts.Read More… Bioxytran Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks19th Percentile Overall ScoreBIXT MarketRank™: Bioxytran scored higher than 19% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Bioxytran. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Bioxytran is -15.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bioxytran is -15.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.01% of the outstanding shares of Bioxytran have been sold short.Short Interest Ratio / Days to CoverBioxytran has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bioxytran has recently decreased by 66.40%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioxytran does not currently pay a dividend.Dividend GrowthBioxytran does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.01% of the outstanding shares of Bioxytran have been sold short.Short Interest Ratio / Days to CoverBioxytran has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bioxytran has recently decreased by 66.40%, indicating that investor sentiment is improving significantly. News and Social Media2.1 / 5News SentimentN/A News SentimentBioxytran has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.Search Interest1 people have searched for BIXT on MarketBeat in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Bioxytran insiders have not sold or bought any company stock.Percentage Held by Insiders70.00% of the stock of Bioxytran is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Bioxytran's insider trading history. Receive BIXT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bioxytran and its competitors with MarketBeat's FREE daily newsletter. Email Address BIXT Stock News HeadlinesBioxytran’s Antiviral Breakthrough Featured in University of Georgia’s $100M HPAI Poultry Innovation Grand Challenge SubmissionMay 21, 2025 | finance.yahoo.comBioxytran's Antiviral Breakthrough Featured in University of Georgia's $100M HPAI Poultry Innovation Grand Challenge SubmissionMay 21, 2025 | globenewswire.com“You all just got a lot richer”Trump Knows What He’s Doing. When the president says he’s going to let RFK “go wild” … and Big Pharma crashes. Do you think that’s an accident? When he threatens to “End the Fed” do you think he doesn’t know banking stocks will benefit? What about when he tells his followers, “Now is a good time to buy,” hours before relaxing tariffs and sending the market soaring? Is that an accident? Larry Benedict doesn’t think so. He thinks Trump knows what he’s doing… and believes he’s found the perfect tickers for everyday Americans to take advantage next time he triggers a big move.May 28, 2025 | Brownstone Research (Ad)BIOXYTRAN, INC.: Bioxytran Completes Dose Optimization of Antiviral, ProLectin-MMay 12, 2025 | finanznachrichten.deBioxytran Completes Dose Optimization of Antiviral, ProLectin-MMay 12, 2025 | globenewswire.comBioxytran Marks 50 years of Mitochondrial Research with BXT-25 AdvancementsApril 11, 2025 | globenewswire.comBioxytran Marks 50 years of Mitochondrial Research with BXT-25 AdvancementsApril 10, 2025 | theglobeandmail.comBioxytran Signs NDA with the University of Georgia to Evaluate Galectin Antagonists for Bird Flu Treatment in ChickensMarch 19, 2025 | globenewswire.comSee More Headlines BIXT Stock Analysis - Frequently Asked Questions How have BIXT shares performed this year? Bioxytran's stock was trading at $0.0899 at the start of the year. Since then, BIXT shares have increased by 76.9% and is now trading at $0.1590. View the best growth stocks for 2025 here. How were Bioxytran's earnings last quarter? Bioxytran, Inc. (OTCMKTS:BIXT) posted its quarterly earnings results on Thursday, May, 15th. The company reported ($0.02) EPS for the quarter. How do I buy shares of Bioxytran? Shares of BIXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bioxytran own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bioxytran investors own include AMC Entertainment (AMC), Armata Pharmaceuticals (ARMP), bluebird bio (BLUE), Esports Entertainment Group (GMBL), Genius Group (GNS), Novavax (NVAX) and Karora Resources Inc. (RNX.TO) (RNX). Company Calendar Last Earnings5/15/2025Today5/28/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:BIXT CIK1445815 Webwww.bioxytraninc.com Phone(617) 454-1199FaxN/AEmployees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$4.47 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-2,100.34% Debt Debt-to-Equity RatioN/A Current Ratio0.03 Quick Ratio0.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / Book-7.86Miscellaneous Outstanding Shares100,173,000Free Float26,440,000Market Cap$15.74 million OptionableNot Optionable Beta1.82 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (OTCMKTS:BIXT) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredTrump Quietly Planning $15 Trillion Crypto ShockerMost investors are still unaware, but I believe a new White House action may have quietly opened the floodgate...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioxytran, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioxytran With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.